Reaction

Vulvovaginal Dryness reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,174 reports · 54 co-occurring drugs

As of the last recalculation, Vulvovaginal Dryness appears in 3,174 FAERS reports alongside 54 co-occurring drug terms. The strongest observed disproportionality signal is ANASTROZOLE (PRR 32.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Anastrozole	171	32.2	32.4
Estradiol	355	30.2	30.3
Conjugated Estrogens	219	26.4	26.5
Estrogens, Conjugated	221	26.2	26.3
Anastrozole Tablets	69	21.5	21.6
Estradiol Gel 0.1%	110	16.5	16.5
Estradiol Transdermal	110	16.5	16.5
Etonogestrel And Ethinyl Estradiol	52	15.6	15.7
Exemestane	50	15.5	15.6
Miconazole Nitrate	20	15.1	15.1
Raloxifene Hydrochloride	32	14.5	14.5
Letrozole	125	13.8	13.8
Fulvestrant	61	12.3	12.3
Goserelin	25	12.3	12.3
Letrozole Tablets	83	11.6	11.6
Thyroid, Porcine	17	10.5	10.5
Abemaciclib	31	10.3	10.3
Leuprolide Acetate	115	10.1	10.1
Ribociclib	47	9.9	9.9
Methylprednisolone Acetate	11	9.0	9.0
Salmeterol Xinafoate	11	8.4	8.4
Alpelisib	11	8.3	8.3
Progesterone	27	7.8	7.8
Pertuzumab	32	7.8	7.8
Granisetron Hydrochloride	12	7.6	7.6
Levonorgestrel	217	7.5	7.5
Etonogestrel	51	7.1	7.1
Granisetron	11	6.9	6.9
Drospirenone And Ethinyl Estradiol	42	6.3	6.3
Medroxyprogesterone Acetate	47	6.3	6.3
Ado-Trastuzumab Emtansine	8	6.2	6.2
Zinc	23	6.2	6.2
Conjugated Estrogens And Medroxyprogesterone Acetate	22	6.1	6.2
Zinc Chloride	23	6.1	6.1
Tolterodine Tartrate	8	5.9	5.9
Zinc Gluconate	23	5.8	5.8
Clobetasol Propionate Ointment Usp, 0.05%	9	5.7	5.7
Vilazodone Hydrochloride	8	5.7	5.7
Trastuzumab	56	5.4	5.4
Naltrexone Hydrochloride And Bupropion Hydrochloride	7	5.4	5.4
Clobetasol Propionate	8	5.1	5.1
Lubiprostone	7	4.9	4.9
Isotretinoin	34	4.5	4.5
Palbociclib	62	4.3	4.3
Zoledronic Acid	25	4.1	4.1
Copper	26	4.0	4.0
Docetaxel Anhydrous	38	3.7	3.7
Docetaxel	38	3.7	3.7
Dexlansoprazole	20	3.2	3.2
Fesoterodine Fumarate	5	3.0	3.0
Canagliflozin	13	2.9	2.9
Lapatinib	6	2.5	2.5
Fam-Trastuzumab Deruxtecan-Nxki	3	2.0	2.0
Bimekizumab	6	1.8	1.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.